Pembrolizumab In Central Nervous System Metastases
Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
This research study is studying Pembrolizumab as a possible treatment for this diagnosis for
metastases in the central nervous system (brain and spinal cord).